CLEVELAND, April 1, 2020 /PRNewswire/ -- ViewRay, Inc.
(Nasdaq: VRAY) announced today a strategic collaboration with
VieCure, an artificial intelligence (AI) informatics company with a
leading point-of-care clinical decision support platform and a
comprehensive electronic medical record (EMR) in oncology. The
collaboration is designed to drive personalized care and treatment
to patients by educating oncology practices on both companies'
precision oncology solutions.
Through the alliance, clinicians will have access to ViewRay's
MRIdian MRI-guided radiation therapy system and VieCure's
VCurePrecision™ EMR platform. VCurePrecision provides a real-time
decision-support system that combines clinical knowledge with
patient data to assist oncologists in generating personalized
treatment plans and managing a patient's care throughout his or her
cancer therapy. ViewRay's MRIdian integrates MRI technology,
radiation delivery, and proprietary software to locate, target, and
track the position and shape of soft-tissue and tumors while
radiation is delivered. MRIdian also offers a powerful gating
feature that automatically controls the radiation beam throughout
each treatment, turning it off if the tumor moves outside of the
targeted treatment area. The combination of MRIdian and
VCurePrecision offers a formidable comprehensive precision oncology
solution.
"Through our collaboration with VieCure, we gain access to a
wider network of oncologists and healthcare systems to offer a
comprehensive cancer treatment and records integration solution,"
said Paul Ziegler, Senior Vice
President of Sales and Marketing at ViewRay. "Both VieCure and
ViewRay are leaders within their field – bringing clinicians a
state-of-the-art AI-powered patient data system and the world's
first MRI-guided radiation therapy system. The ability to deliver
these world-class solutions together is a real benefit to oncology
practices interested in advancing personalized treatment to improve
patient outcomes."
"Oncologists are embracing the paradigm shift toward data-driven
precision medicine, but they face a myriad of clinical workflow and
content-related challenges," said Fred
Ashbury, Ph.D., Chief Scientific Officer at VieCure. "Our
platform combines patient data with leading scientific knowledge in
radiation oncology, systemic therapy and surgical oncology, and
generates individualized treatment prescriptions throughout the
patient's diagnosis and care journey. We are excited to deliver
even better insights to the multidisciplinary clinical team and the
participating radiation oncologists, medical physicists, therapists
and treatment planners who will use our A.I. enabled smart
EMR."
VieCure's oncology-specific and AI-enabled VCurePrecision
platform is aimed at both private practice cancer centers and large
provider organizations as a point-of-care solution to collect,
curate, streamline and manage diagnostic and treatment options
ranging from molecular test results through patient-reported
outcomes. The platform also incorporates AI clinical rules to
personalize standard of care to the specific characteristics of an
individual's cancer.
Currently 34 MRIdian systems are installed at hospitals around
the world, where they are being used to treat a wide variety of
solid tumors and are the focus of numerous ongoing research
initiatives. MRIdian has been the subject of hundreds of
peer-reviewed publications, scientific meeting abstracts and
presentations. More than 8,000 patients have been treated with
MRIdian. For a list of treatment centers, please visit:
https://viewray.com/mridian-locator.
About ViewRay
ViewRay®, Inc. (Nasdaq:
VRAY), designs, manufactures, and markets the MRIdian® radiation
therapy system. MRIdian is built upon a proprietary high-definition
MR imaging system designed from the ground up to address the unique
challenges and clinical workflow for advanced radiation oncology.
Unlike MR systems used in diagnostic radiology, MRIdian's
high-definition MR was purposely built to deliver high-precision
radiation without unnecessary beam distortion, and consequently,
help to mitigate skin toxicity and other safety concerns that may
otherwise arise when high magnetic fields interact with radiation
beams.
About VieCure
VieCure has developed a proprietary
artificial intelligence informatics software platform in
conjunction with a clinical inference engine and smart electronic
medical record in oncology. The VCurePrecision™ platform is a
real-time decision support system that combines clinical knowledge
with patient data to assist oncologists and hematologists in
generating personalized treatment plans and managing a patient's
treatment throughout diagnosis, cancer therapy, and ongoing
follow-up care. For more information, please visit viecure.com and
connect with VieCure on LinkedIn, Facebook and YouTube.
Forward Looking Statements:
This press release
contains forward-looking statements within the meaning of Section
27A of the Private Securities Litigation Reform Act. Statements in
this press release that are not purely historical are
forward-looking statements. Such forward-looking statements
include, among other things, the rate of new orders, upgrades and
installations, ViewRay's financial guidance for the full year 2020
and ViewRay's conference calls to discuss its fourth quarter 2019
and year to date results. Actual results could differ from those
projected in any forward-looking statements due to numerous
factors. Such factors include, among others, the ability to
commercialize MRIdian Linac System, demand for ViewRay's products,
the ability to convert backlog into revenue, and the timing of
delivery of ViewRay's products, the timing, results and other
uncertainties associated with clinical trials, the ability to raise
the additional funding needed to continue to pursue ViewRay's
business and product development plans, the inherent uncertainties
associated with developing new products or technologies,
competition in the industry in which ViewRay operates and overall
market conditions. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to ViewRay's business in general, see ViewRay's current
and future reports filed with the Securities and Exchange
Commission, including its Annual Report on Form 10-K for the fiscal
year ended December 31, 2019 and its
2019 Quarterly Reports on Form 10-Q, as updated periodically with
the company's other filings with the SEC. These forward-looking
statements are made as of the date of this press release, and
ViewRay assumes no obligation to update the forward-looking
statements, or to update the reasons why actual results could
differ from those projected in the forward-looking statements,
except as required by law.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/viewray-and-viecure-announce-strategic-collaboration-to-accelerate-adoption-of-personalized-cancer-care-301033058.html
SOURCE ViewRay, Inc.